Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 2/20 | 0.45 |
| ▸ | CYCS | P99999 | 3/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | TERT | O14746 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10314953 | 0.85 | TOP1 (0.46) | TOP1CYCSENPP2TERT | |
| SCHEMBL10314824 | 0.80 | ABCG2 (0.57) | TOP1CYCSENPP2TERTIDO1 | |
| SCHEMBL30039384 | 0.74 | TERT (0.46) | TOP1CYCSTERT | |
| SCHEMBL4881460 | 0.74 | TERT (0.46) | TOP1CYCSTERT | |
| SCHEMBL31258522 | 0.72 | TERT (0.45) | TOP1CYCSTERT | |
| SCHEMBL29808674 | 0.69 | TERT (0.41) | TOP1CYCSENPP2TERT | |
| SCHEMBL14571998 | 0.69 | TERT (0.53) | TOP1CYCSENPP2TERT | |
| Zinc Ion SCHEMBL31453018 | 0.68 | TOP1 (0.58) | TOP1CYCSENPP2TERT | |
| SCHEMBL30968084 | 0.68 | TOP1 (0.84) | TOP1CYCSENPP2TERT | |
| Hydrochloric Acid SCHEMBL1409233 | 0.68 | TERT (0.52) | TOP1CYCSENPP2TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9289434-B2 | Substituted porphyrins | AEOLUS SCIENCES, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9289434-B2 | Substituted porphyrins | AEOLUS SCIENCES, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9289434-B2 | Substituted porphyrins | AEOLUS SCIENCES, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150231150-A1 | SUBSTITUTED PORPHYRINS | AEOLUS PHARMACEUTICALS INC. | 2015-08-20 | — | — | US | disclosed |
| US-20150231150-A1 | SUBSTITUTED PORPHYRINS | AEOLUS PHARMACEUTICALS INC. | 2015-08-20 | — | — | US | disclosed |
| US-20150231150-A1 | SUBSTITUTED PORPHYRINS | AEOLUS PHARMACEUTICALS INC. | 2015-08-20 | — | — | US | disclosed |
| US-8946202-B2 | Substituted porphyrins | AEOLUS SCIENCES, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946202-B2 | Substituted porphyrins | AEOLUS SCIENCES, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946202-B2 | Substituted porphyrins | AEOLUS SCIENCES, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140011794-A1 | SUBSTITUTED PORPHYRINS | Aeouls Sciences, Inc. (US) | 2014-01-09 | — | — | US | disclosed |
| US-20070197496-A1 | for modulating cellular levels of oxidants such as superoxide radicals, hydrogen peroxide, peroxynitrite, lipid peroxides, hydroxyl radicals and thiyl radicals, treating diabetes mellitus Type I or Type II | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER | 2007-08-23 | — | — | US | disclosed |
| US-20070197496-A1 | for modulating cellular levels of oxidants such as superoxide radicals, hydrogen peroxide, peroxynitrite, lipid peroxides, hydroxyl radicals and thiyl radicals, treating diabetes mellitus Type I or Type II | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER | 2007-08-23 | — | — | US | disclosed |
| US-20070197496-A1 | for modulating cellular levels of oxidants such as superoxide radicals, hydrogen peroxide, peroxynitrite, lipid peroxides, hydroxyl radicals and thiyl radicals, treating diabetes mellitus Type I or Type II | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER | 2007-08-23 | — | — | US | disclosed |
| US-7189707-B2 | Substituted porphyrins | NATIONAL JEWISH MEDICAL RESEARCH CENTER (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189707-B2 | Substituted porphyrins | NATIONAL JEWISH MEDICAL RESEARCH CENTER (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189707-B2 | Substituted porphyrins | NATIONAL JEWISH MEDICAL RESEARCH CENTER (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1616869-A1 | Substituted porphyrins and their therapeutic use | National Jewish Medical and Research Center (US) | 2006-01-18 | — | — | EP | disclosed |
| EP-1155019-B1 | SUBSTITUTED PORPHYRINS AND THEIR THERAPEUTIC USE | NAT JEWISH MED & RES CENTER (US) | 2005-12-07 | — | — | EP | disclosed |
| US-20040023941-A1 | Modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER | 2004-02-05 | — | — | US | disclosed |
| US-6544975-B1 | Mimetics that inhibit lipid peroxidation; for use in the treatment of diseases or disorders mediated by oxidative stress, such as asthma, inflammatory bowel disease, arthritis and vasculitis. | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER | 2003-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150231150-A1 | SUBSTITUTED PORPHYRINS | PPOX, GPX4, PRDX5 | TOP1 4291/4885CYCS 76/4885ENPP2 399/4885 |
| US-20040023941-A1 | Modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and | TXN2, PRDX5, GPX4 | TOP1 4748/4885CYCS 220/4885ENPP2 212/4885 |
| US-20140011794-A1 | SUBSTITUTED PORPHYRINS | PPOX, GPX4, PRDX5 | TOP1 4291/4885CYCS 76/4885ENPP2 399/4885 |
| US-20070197496-A1 | for modulating cellular levels of oxidants such as superoxide radicals, hydrogen peroxide, peroxynitrite, lipid peroxides, hydroxyl radicals and thiyl radicals, treating diabetes mellitus Type I or Type II | GPX4, LPO, TXNRD2 | TOP1 3334/4885CYCS 294/4885ENPP2 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.